Literature DB >> 1721667

Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.

S Meri1, H Waldmann, P J Lachmann.   

Abstract

Protectin (CD59) is a recently discovered 18-20 kDa glycoprotein that effectively inhibits lysis by the membrane attack complex of the homologous complement system. This glycoprotein is widely distributed on the membranes of human blood cells (erythrocytes and leukocytes). By using immunofluorescence microscopy, protectin was observed in vascular endothelia throughout the body and in extravascular tissues. Cells expressing protectin were also found in ductal epithelia of pancreatic, biliary, and salivary systems, bronchi, and kidney collecting ducts. Furthermore, protectin was expressed in the epidermis and in the syncytiotrophoblast of placenta. The expression of protectin in endothelia, in various epithelial cells, and in placenta presumably protects autologous tissues and the fetoplacental unit from complement-mediated damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721667

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  62 in total

1.  CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.

Authors:  Imre Farkas; Lajos Baranyi; Yasushige Ishikawa; Noriko Okada; Csaba Bohata; Denes Budai; Atsuo Fukuda; Masaki Imai; Hidechika Okada
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

2.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid.

Authors:  I A Rooney; B P Morgan
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.

Authors:  M Paula Longhi; Baalasubramanian Sivasankar; Nader Omidvar; B Paul Morgan; Awen Gallimore
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 6.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

7.  Characterization in vitro and in vivo of the pig analogue of human CD59 using new monoclonal antibodies.

Authors:  S M Hanna; G T Williams; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

8.  Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.

Authors:  H Dauchel; P Joly; A Delpech; E Thomine; F Sauger; X Le Loet; P Lauret; F Tron; M Fontaine; J Ripoche
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

Authors:  A Mäenpää; S Junnikkala; J Hakulinen; T Timonen; S Meri
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  Analysis of human CD59 tissue expression directed by the CMV-IE-1 promoter in transgenic rats.

Authors:  B Charreau; L Tesson; J Buscail; J P Soulillou; I Anegon
Journal:  Transgenic Res       Date:  1996-11       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.